<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC7122614\results\search\drugs\results.xml">
  <result pre="contained the His275Tyr mutation and were therefore highly resistant to" exact="oseltamivir" post="while retaining susceptibility to zanamivir. All currently circulating A/H1N1"/>
  <result pre="acids in the M2 gene result in cross-resistance to both" exact="amantadine" post="and rimantadine. Resistance emergence during therapy with neuraminidase inhibitors"/>
  <result pre="[17]. There are currently two approved M2 ion channel inhibitors," exact="amantadine" post="and rimantadine. Early studies demonstrated that influenza variants with"/>
  <result pre="Early studies demonstrated that influenza variants with high-level resistance to" exact="amantadine" post="and rimantadine could be selected in the laboratory though"/>
  <result pre="demonstrated that influenza variants with high-level resistance to amantadine and" exact="rimantadine" post="could be selected in the laboratory though in vitro"/>
  <result pre="of influenza A/H1N1, A/H2N2, and A/H3N2 were initially susceptible to" exact="amantadine" post="and rimantadine [19, 24, 39, 42]. Even after licensure"/>
  <result pre="A/H1N1, A/H2N2, and A/H3N2 were initially susceptible to amantadine and" exact="rimantadine" post="[19, 24, 39, 42]. Even after licensure of the"/>
  <result pre="the M2 inhibitors, possibly related to increased use of over-the-counter" exact="amantadine" post="after the emergence of severe acute respiratory syndrome (SARS)"/>
  <result pre="EIA enzyme immunoassay aAll resistant viruses from family members receiving" exact="rimantadine" post="bOver 80 % of tested isolates were H3N2 subtype"/>
  <result pre="resistant virus could be detected in 50 % of six" exact="rimantadine" post="recipients by day 3 of treatment, although the nasal"/>
  <result pre="33 % of 24 adult and pediatric household members receiving" exact="rimantadine" post="shed resistant virus on day 5 of treatment; none"/>
  <result pre="found emergence of resistant virus in 27 % of 37" exact="rimantadine" post="recipients, including 45 % of those still virus positive"/>
  <result pre="positive on day 7, compared to 6 % of 32" exact="acetaminophen" post="recipients [23]. Resistant virus was detected as early as"/>
  <result pre="on days 5–7. A study of Japanese children treated with" exact="amantadine" post="found that 30 % of 81 in the 1999–2000"/>
  <result pre="80 % of 15 hospitalized children during or immediately after" exact="amantadine" post="treatment [41]. Nine (75 %) of 12 children had"/>
  <result pre="randomized study patients hospitalized with influenza were to receive either" exact="rimantadine" post="alone or rimantadine plus nebulized zanamivir [54]. Rimantadine-resistant virus"/>
  <result pre="hospitalized with influenza were to receive either rimantadine alone or" exact="rimantadine" post="plus nebulized zanamivir [54]. Rimantadine-resistant virus was detected in"/>
  <result pre="were to receive either rimantadine alone or rimantadine plus nebulized" exact="zanamivir" post="[54]. Rimantadine-resistant virus was detected in 2/20 (10 %)"/>
  <result pre="[54]. Rimantadine-resistant virus was detected in 2/20 (10 %) of" exact="rimantadine" post="monotherapy patients, while non-resistant variants were detected in the"/>
  <result pre="(38 %) H3N2 Englund et al. [28] 1993–1994 Immunocompromised Amantadine," exact="rimantadine" post="15 5 (33 %) H3N2 Saito et al. [53]"/>
  <result pre="Contact birds shedding resistant virus due to earlier incorporation of" exact="amantadine" post="in the drinking water of donors (4 days only)"/>
  <result pre="of four experiments over four cumulative transmission cycles. Households Both" exact="amantadine" post="and rimantadine are effective for postexposure prophylaxis of illness"/>
  <result pre="experiments over four cumulative transmission cycles. Households Both amantadine and" exact="rimantadine" post="are effective for postexposure prophylaxis of illness due to"/>
  <result pre="reduction in secondary influenza illness in household contacts receiving either" exact="amantadine" post="or rimantadine for postexposure prophylaxis, when the ill index"/>
  <result pre="secondary influenza illness in household contacts receiving either amantadine or" exact="rimantadine" post="for postexposure prophylaxis, when the ill index cases received"/>
  <result pre="a persistent or an increasing number of virus-positive patients despite" exact="amantadine" post="prophylaxis. The recovery of the same genotype of resistant"/>
  <result pre="nursing home outbreak [58]. The frequency of instances in which" exact="amantadine" post="or rimantadine has failed to control outbreaks because of"/>
  <result pre="outbreak [58]. The frequency of instances in which amantadine or" exact="rimantadine" post="has failed to control outbreaks because of resistance emergence"/>
  <result pre="occasional patients wild-type virus replaces resistant variants after cessation of" exact="amantadine" post="[41]. As noted for some avian A/H7 viruses, this"/>
  <result pre="when resistance emerges as well [23]. Treatment Alternatives Amantadine and" exact="rimantadine" post="share susceptibility and resistance, so that resistance to one"/>
  <result pre="of suspected M2 inhibitor-resistant infections. Clinical studies suggest that both" exact="oseltamivir" post="and zanamivir are successful in terminating institutional outbreaks where"/>
  <result pre="M2 inhibitor-resistant infections. Clinical studies suggest that both oseltamivir and" exact="zanamivir" post="are successful in terminating institutional outbreaks where amantadine resistance"/>
  <result pre="oseltamivir and zanamivir are successful in terminating institutional outbreaks where" exact="amantadine" post="resistance is proven or highly probable [58, 62, 63]."/>
  <result pre="62, 63]. In vitro testing suggests that the synthetic nucleosides" exact="ribavirin" post="and favipiravir are also inhibitory for M2 inhibitor-resistant influenza"/>
  <result pre="be an option. A small study randomized hospitalized adults to" exact="rimantadine" post="monotherapy or rimantadine-nebulized zanamivir combination therapy. The combination arm"/>
  <result pre="small study randomized hospitalized adults to rimantadine monotherapy or rimantadine-nebulized" exact="zanamivir" post="combination therapy. The combination arm had a trend to"/>
  <result pre="therapy [54]. Recently, a triple combination of amantadine, oseltamivir, and" exact="ribavirin" post="has been studied in vitro, in vivo, and in"/>
  <result pre="determine the genetic antiviral resistance profiles of the NA inhibitors" exact="zanamivir" post="and oseltamivir were initiated shortly after their development (reviewed"/>
  <result pre="genetic antiviral resistance profiles of the NA inhibitors zanamivir and" exact="oseltamivir" post="were initiated shortly after their development (reviewed in [70,"/>
  <result pre="late 1990s that served as the basis for approval of" exact="zanamivir" post="and oseltamivir in 1999 and, more recently, for approval"/>
  <result pre="that served as the basis for approval of zanamivir and" exact="oseltamivir" post="in 1999 and, more recently, for approval of laninamivir"/>
  <result pre="in 1999 and, more recently, for approval of laninamivir and" exact="peramivir" post="[83–87]. Although zanamivir and oseltamivir have been available in"/>
  <result pre="more recently, for approval of laninamivir and peramivir [83–87]. Although" exact="zanamivir" post="and oseltamivir have been available in many countries since"/>
  <result pre="for approval of laninamivir and peramivir [83–87]. Although zanamivir and" exact="oseltamivir" post="have been available in many countries since 1999, their"/>
  <result pre="182) had significantly fewer days of fever if treated with" exact="oseltamivir" post="(n = 64) as compared to non-treated patients (n"/>
  <result pre="an oseltamivir-resistant viruses (n = 44) did not benefit from" exact="oseltamivir" post="treatment (n = 43; P = 0.5) [91]. Similar"/>
  <result pre="patterns of cross-resistance are found for particular NA mutations. Importantly," exact="zanamivir" post="and laninamivir retain full inhibitory activity against variants with"/>
  <result pre="resistance [115–117]. Table 71.4 Effects of NA mutations that confer" exact="oseltamivir" post="resistance on viral fitness measures in clinical isolates of"/>
  <result pre="patients (1.9 %) receiving an antiviral, emergence of resistance to" exact="oseltamivir" post="could be detected during treatment, in most cases children"/>
  <result pre="an His274Tyr are a reason for concern [122–124]. Resistance to" exact="zanamivir" post="was reported due to an amino change Gln136Lys [125,"/>
  <result pre="causing an 80-fold and sevenfold increase of the IC50 for" exact="oseltamivir" post="and zanamivir, respectively [134–137]. This Asn295Ser change has also"/>
  <result pre="in China since 2013 causes high NA inhibitor resistance to" exact="oseltamivir" post="and peramivir and reduced resistance to zanamivir [138, 139]."/>
  <result pre="since 2013 causes high NA inhibitor resistance to oseltamivir and" exact="peramivir" post="and reduced resistance to zanamivir [138, 139]. Unlike A/H3N2"/>
  <result pre="inhibitor resistance to oseltamivir and peramivir and reduced resistance to" exact="zanamivir" post="[138, 139]. Unlike A/H3N2 viruses carrying the Arg292Lys amino"/>
  <result pre="to oseltamivir, zanamivir, and peramivir. Table 71.5 Representative studies of" exact="oseltamivir" post="and zanamivir susceptibility of field isolates of influenza A"/>
  <result pre="zanamivir, and peramivir. Table 71.5 Representative studies of oseltamivir and" exact="zanamivir" post="susceptibility of field isolates of influenza A and B"/>
  <result pre="chain reaction aOne B/Perth/211/2001 isolate had ninefold reduced susceptibility to" exact="zanamivir" post="and 14-fold to oseltamivir compared to the mean inhibitory"/>
  <result pre="isolate had ninefold reduced susceptibility to zanamivir and 14-fold to" exact="oseltamivir" post="compared to the mean inhibitory concentrations of influenza B"/>
  <result pre="analysis of samples from over 2500 influenza patients treated with" exact="oseltamivir" post="as outpatients indicated that the frequency of resistance detection"/>
  <result pre="Japanese children reported high frequencies of 16 and 18 %" exact="oseltamivir" post="resistance emergence during oseltamivir therapy [8, 147]. The use"/>
  <result pre="frequencies of 16 and 18 % oseltamivir resistance emergence during" exact="oseltamivir" post="therapy [8, 147]. The use of weight-based dosing for"/>
  <result pre="a replication advantage over viruses with human receptor preference during" exact="oseltamivir" post="use in humans. Interestingly, amino acid changes in the"/>
  <result pre="change [149, 150]. Table 71.6 Frequency of resistance emergence to" exact="oseltamivir" post="or zanamivir during treatment Drug/study Population Assay Virus type"/>
  <result pre="150]. Table 71.6 Frequency of resistance emergence to oseltamivir or" exact="zanamivir" post="during treatment Drug/study Population Assay Virus type No. isolates"/>
  <result pre="0 aThese pediatric studies used a 2 mg/kg dose of" exact="oseltamivir" post="that has been shown to give reduced drug exposure"/>
  <result pre="impact on therapy is unclear for such moderate increase in" exact="oseltamivir" post="resistance; however viruses with the combination of Ile223Arg and"/>
  <result pre="the combination of Ile223Arg and His275Tyr are highly resistant to" exact="oseltamivir" post="in vitro (1750-fold) [160]. In the past, emergence of"/>
  <result pre="for influenza A/H3N2 and influenza B virus-infected patients treated with" exact="oseltamivir" post="and zanamivir with mutations in both the viral HA"/>
  <result pre="A/H3N2 and influenza B virus-infected patients treated with oseltamivir and" exact="zanamivir" post="with mutations in both the viral HA and NA"/>
  <result pre="have been suggested to have facilitated the emergence of this" exact="oseltamivir" post="resistance change. The Asp344Asn amino acid change, which appeared"/>
  <result pre="compensate for the loss of fitness due to the Glu119Val" exact="oseltamivir" post="resistance mutation [170, 171]. The observed community clusters of"/>
  <result pre="inhibitor cross-resistance vary by virus type and subtype, such that" exact="zanamivir" post="retains inhibitory activity for the most common resistant variants"/>
  <result pre="common resistant variants that emerge during the therapeutic use of" exact="oseltamivir" post="or peramivir. Zanamivir is fully inhibitory for oseltamivir-resistant variants"/>
  <result pre="in N1 [102, 172]. Depending on the virus and assay," exact="zanamivir" post="is partially inhibitory for resistant variants with Arg292Lys substitution"/>
  <result pre="type [102, 172–174]. There is controversy about the role of" exact="peramivir" post="in the management of variants that are resistant to"/>
  <result pre="peramivir in the management of variants that are resistant to" exact="oseltamivir" post="as in vitro and in vivo models have given"/>
  <result pre="mutation in influenza B NA that confers reduced susceptibility to" exact="zanamivir" post="[178]. Given these findings, most experts recommend using zanamivir"/>
  <result pre="to zanamivir [178]. Given these findings, most experts recommend using" exact="zanamivir" post="for the treatment of patients who develop resistance or"/>
  <result pre="patients who develop resistance or virologic failure to oseltamivir. Inhaled" exact="zanamivir" post="has been utilized in a few patients with variable"/>
  <result pre="is less likely in patients with influenza pneumonia [179–182]. Intravenous" exact="zanamivir" post="has been utilized most frequently for patients with proven"/>
  <result pre="prior exposure to numerous interventions [183–186]. Other NA inhibitors and" exact="zanamivir" post="dimers that have prolonged duration of antiviral effect after"/>
  <result pre="experimentally infected with influenza A, the combination of orally administered" exact="ribavirin" post="and peramivir was associated with improved survival relative to"/>
  <result pre="with influenza A, the combination of orally administered ribavirin and" exact="peramivir" post="was associated with improved survival relative to ribavirin alone"/>
  <result pre="ribavirin and peramivir was associated with improved survival relative to" exact="ribavirin" post="alone but not to peramivir alone [189]. A more"/>
  <result pre="with improved survival relative to ribavirin alone but not to" exact="peramivir" post="alone [189]. A more recent study found that a"/>
  <result pre="[189]. A more recent study found that a combination of" exact="ribavirin" post="and oseltamivir was no more effective than ribavirin alone"/>
  <result pre="more recent study found that a combination of ribavirin and" exact="oseltamivir" post="was no more effective than ribavirin alone against a"/>
  <result pre="combination of ribavirin and oseltamivir was no more effective than" exact="ribavirin" post="alone against a lethal influenza A(H1N1) infection but superior"/>
  <result pre="M2 inhibitor-resistant viruses. Recently, triple combinations of amantadine, ribavirin, and" exact="oseltamivir" post="have been studied in vitro, in vivo, and in"/>
  <result pre="therapy. Given its slightly broader activity against most oseltamivir-resistant variants," exact="zanamivir" post="would be the preferred therapy for patients with proven"/>
  <result pre="polymerase inhibitor favipiravir [191], the receptor-destroying sialidase DAS181 [199], and" exact="nitazoxanide" post="[200]. Neutralizing antibodies and convalescent plasma need to be"/>
  <result pre="Pt B):159–73. 6.GovorkovaEAet al.Comparison of efficacies of RWJ-270201, zanamivir, and" exact="oseltamivir" post="against H5N1, H9N2, and other avian influenza virusesAntimicrob Agents"/>
  <result pre="nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virusJAMA2009301101042610.1001/jama.2009.29719255111 12.GubarevaLVet al.Evidence for" exact="zanamivir" post="resistance in an immunocompromised child infected with influenza B"/>
  <result pre="of influenza pandemic preparedness in developing countriesEmerg Infect Dis20081468758010.3201/eid1406.07083918507896 17.HaydenFGAokiFYBarriereSLAmantadine," exact="rimantadine" post="and related agentsAntimicrobial therapy and vaccines1999Baltimore, MDWilliams and Wilkins134465"/>
  <result pre="vaccines1999Baltimore, MDWilliams and Wilkins134465 18.BelsheRBet al.Genetic basis of resistance to" exact="rimantadine" post="emerging during treatment of influenza virus infectionJ Virol19886251508123282079 19.HayAJRichmanDDAmantadine"/>
  <result pre="treatment with rimantadinePediatrics1987802275823302925 24.BelsheRBet al.Resistance of influenza A virus to" exact="amantadine" post="and rimantadine: results of one decade of surveillanceJ Infect"/>
  <result pre="N1 neuraminidase subtypeJ Virol201084199800910.1128/JVI.00296-1020660186 35.MarjukiHet al.Neuraminidase mutations conferring resistance to" exact="oseltamivir" post="in influenza A(H7N9) virusesJ Virol2015891054192610.1128/JVI.03513-1425740997 36.MarjukiHet al.Characterization of drug-resistant"/>
  <result pre="and H3N2J Clin Microbiol20034152164510.1128/JCM.41.5.2164-2165.200312734269 54.IsonMGet al.Safety and efficacy of nebulized" exact="zanamivir" post="in hospitalized patients with serious influenzaAntivir Ther2003831839012924534 55.KlimovAIet al.Prolonged"/>
  <result pre="Rocha Crispino Santos, and A.J. Alves da Cunha, Amantadine and" exact="rimantadine" post="for influenza A in children and the elderly. Cochrane"/>
  <result pre="amantadine-resistant influenza a viruses (H3N2) from patients following administration of" exact="amantadine" post="in JapanJ Clin Microbiol20013941652310.1128/JCM.39.4.000-000.200111283109 61.DegelauJet al.Amantadine-resistant influenza A in"/>
  <result pre="A in a nursing facilityArch Intern Med19921522390210.1001/archinte.1992.004001401280271739371 62.BowlesSKet al.Use of" exact="oseltamivir" post="during influenza outbreaks in Ontario nursing homes, 1999–2000J Am"/>
  <result pre="Ontario nursing homes, 1999–2000J Am Geriatr Soc20025046081610.1046/j.1532-5415.2002.50153.x11982659 63.HirjiZet al.Utility of" exact="zanamivir" post="for chemoprophylaxis of concomitant influenza A and B in"/>
  <result pre="T-705Antimicrob Agents Chemother20024649778110.1128/AAC.46.4.977-981.200211897578 65.NguyenJTet al.Triple combination of amantadine, ribavirin, and" exact="oseltamivir" post="is highly active and synergistic against drug resistant influenza"/>
  <result pre="One201052e933210.1371/journal.pone.000933220179772 66.NguyenJTet al.Efficacy of combined therapy with amantadine, oseltamivir, and" exact="ribavirin" post="in vivo against susceptible and amantadine-resistant influenza A virusesPLoS"/>
  <result pre="virusesPLoS Pathog2014104e100406510.1371/journal.ppat.100406524699865 80.BloomJDGongLIBaltimoreDPermissive secondary mutations enable the evolution of influenza" exact="oseltamivir" post="resistanceScience201032859831272510.1126/science.118781620522774 81.LiYet al.Single hemagglutinin mutations that alter both antigenicity"/>
  <result pre="R Soc Interface201411922013108310.1098/rsif.2013.108324430126 83.SugayaNet al.Efficacy, safety, and pharmacokinetics of intravenous" exact="peramivir" post="in children with 2009 pandemic H1N1 influenza A virus"/>
  <result pre="Chemother20125613697710.1128/AAC.00132-1122024821 84.KohnoSet al.Phase III randomized, double-blind study comparing single-dose intravenous" exact="peramivir" post="with oral oseltamivir in patients with seasonal influenza virus"/>
  <result pre="III randomized, double-blind study comparing single-dose intravenous peramivir with oral" exact="oseltamivir" post="in patients with seasonal influenza virus infectionAntimicrob Agents Chemother2011551152677610.1128/AAC.00360-1121825298"/>
  <result pre="inhibitorExpert Opin Pharmacother20151612188990010.1517/14656566.2015.106633626153242 86.WatanabeAet al.Long-acting neuraminidase inhibitor laninamivir octanoate versus" exact="oseltamivir" post="for treatment of influenza: a double-blind, randomized, noninferiority clinical"/>
  <result pre="trialClin Infect Dis2010511011677510.1086/65680220936975 87.SugayaNOhashiYLong-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus" exact="oseltamivir" post="as treatment for children with influenza virus infectionAntimicrob Agents"/>
  <result pre="II clinical efficacy studiesJ Antimicrob Chemother.2000441788710.1128/AAC.44.1.78-87.2000 89.KawaiNet al.Clinical effectiveness of" exact="oseltamivir" post="and zanamivir for treatment of influenza A virus subtype"/>
  <result pre="efficacy studiesJ Antimicrob Chemother.2000441788710.1128/AAC.44.1.78-87.2000 89.KawaiNet al.Clinical effectiveness of oseltamivir and" exact="zanamivir" post="for treatment of influenza A virus subtype H1N1 with"/>
  <result pre="and 2008–2009 influenza seasonsClin Infect Dis2009491218283510.1086/64842419911968 90.KawaiNet al.Clinical effectiveness of" exact="oseltamivir" post="for influenza A(H1N1) virus with H274Y neuraminidase mutationJ Infect20095932071210.1016/j.jinf.2009.07.00219619898"/>
  <result pre="A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of" exact="oseltamivir" post="and zanamivirVirol J201075310.1186/1743-422X-7-5320202225 93.SaitoRet al.Reduced effectiveness of oseltamivir in"/>
  <result pre="effectiveness of oseltamivir and zanamivirVirol J201075310.1186/1743-422X-7-5320202225 93.SaitoRet al.Reduced effectiveness of" exact="oseltamivir" post="in children infected with oseltamivir-resistant influenza A (H1N1) viruses"/>
  <result pre="influenza viruses A (H1N1), Norway, 2007–08Emerg Infect Dis20091521556210.3201/eid1502.08103119193257 95.BesselaarTGet al.Widespread" exact="oseltamivir" post="resistance in influenza A viruses (H1N1), South AfricaEmerg Infect"/>
  <result pre="Interface20129696485610.1098/rsif.2011.042721865253 97.CarrJet al.Influenza virus carrying neuraminidase with reduced sensitivity to" exact="oseltamivir" post="carboxylate has altered properties in vitro and is compromised"/>
  <result pre="99.BazMet al.Effect of the neuraminidase mutation H274Y conferring resistance to" exact="oseltamivir" post="on the replicative capacity and virulence of old and"/>
  <result pre="assays for quantitative and qualitative detection of influenza virus and" exact="oseltamivir" post="resistance mutationsJ Mol Diagn20131533475410.1016/j.jmoldx.2012.11.00723597879 108.DeydeVMet al.Pyrosequencing as a tool"/>
  <result pre="virus resistance to neuraminidase inhibitorsVirus Res20041031–219920310.1016/j.virusres.2004.02.03415163510 113.CollinsPJet al.Structural basis for" exact="oseltamivir" post="resistance of influenza virusesVaccine2009274563172310.1016/j.vaccine.2009.07.01719840667 114.SamsonMet al.Characterization of drug-resistant influenza"/>
  <result pre="influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with" exact="oseltamivir" post="and zanamivirJ Infect Dis2015212812091310.1093/infdis/jiv24525943200 116.NguyenHTet al.Recovery of a multidrug-resistant"/>
  <result pre="al.A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to" exact="oseltamivir" post="and peramivir in Japan, November to December 2013Euro Surveill.20141912066610.2807/1560-7917.ES2014.19.1.2066624434172"/>
  <result pre="cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and" exact="peramivir" post="in Japan, November to December 2013Euro Surveill.20141912066610.2807/1560-7917.ES2014.19.1.2066624434172 125.HurtACet al.Zanamivir-resistant"/>
  <result pre="a Q136K mutation in the neuraminidase gene is resistant to" exact="zanamivir" post="but exhibits reduced fitness in the guinea pig transmission"/>
  <result pre="patients infected with I221V influenza B virus variants with reduced" exact="oseltamivir" post="susceptibility—North Carolina and South Carolina, 2010–2011J Infect Dis201320769667310.1093/infdis/jis77623242536 146.RobertsNATreatment"/>
  <result pre="fitness contributed by secondary mutations in the hemagglutinin protein of" exact="oseltamivir" post="resistant H1N1 influenza viruses: modeling studies of antibody and"/>
  <result pre="cancerPediatr Infect Dis J2011304284810.1097/INF.0b013e3181ff863b21048522 158.FraaijPLet al.Viral shedding and susceptibility to" exact="oseltamivir" post="in hospitalized immunocompromised patients with influenza in the Influenza"/>
  <result pre="H274Y mutation in the influenza A/H1N1 neuraminidase active site following" exact="oseltamivir" post="phosphate treatment leave virus severely compromised both in vitro"/>
  <result pre="N1 and N2 genetic backgroundsAntivir Ther2006118971617302366 173.MishinVPet al.Evaluation of methyl" exact="inosine" post="monophosphate (MIMP) and peramivir activities in a murine model"/>
  <result pre="backgroundsAntivir Ther2006118971617302366 173.MishinVPet al.Evaluation of methyl inosine monophosphate (MIMP) and" exact="peramivir" post="activities in a murine model of lethal influenza A"/>
  <result pre="fitness and transmissibilityAntimicrob Agents Chemother2005491040758410.1128/AAC.49.10.4075-4084.200516189083 175.Abed Y et al. Parenteral" exact="peramivir" post="treatment for Oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses."/>
  <result pre="Infect Dis. 2011;204(10):1641–2; author’s reply 1642–3. 176.AbedYPizzornoABoivinGTherapeutic activity of intramuscular" exact="peramivir" post="in mice infected with a recombinant influenza A/WSN/33 (H1N1)"/>
  <result pre="(H1N1) 2009, United StatesEmerg Infect Dis2011172255710.3201/eid1702.10172421291599 181.JohnyAAet al.The use of" exact="zanamivir" post="to treat influenza A and B infection after allogeneic"/>
  <result pre="stem cell transplantationBone Marrow Transplant2002292113510.1038/sj.bmt.170334311850704 182.PetersenEet al.Failure of combination oral" exact="oseltamivir" post="and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated"/>
  <result pre="Marrow Transplant2002292113510.1038/sj.bmt.170334311850704 182.PetersenEet al.Failure of combination oral oseltamivir and inhaled" exact="zanamivir" post="antiviral treatment in ventilator- and ECMO-treated critically ill patients"/>
  <result pre="A (H1N1)vScand J Infect Dis2011436–749550310.3109/00365548.2011.55614421309638 183.Chan-TackKMet al.Clinical experience with intravenous" exact="zanamivir" post="under an emergency investigational new drug program in the"/>
  <result pre="the United StatesJ Infect Dis20132071196810.1093/infdis/jis63723089591 184.Chan-TackKMet al.Clinical experience with intravenous" exact="zanamivir" post="under an Emergency IND program in the United States"/>
  <result pre="States (2011–2014)Antivir Ther2015205561410.3851/IMP294425667992 185.FraaijPLet al.Evaluation of the antiviral response to" exact="zanamivir" post="administered intravenously for treatment of critically ill patients with"/>
  <result pre="the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirinChemotherapy2002482889310.1159/00005766812011541 189.SmeeDFet al.Activities of" exact="oseltamivir" post="and ribavirin used alone and in combination against infections"/>
  <result pre="neuraminidase inhibitor RWJ-270201 and ribavirinChemotherapy2002482889310.1159/00005766812011541 189.SmeeDFet al.Activities of oseltamivir and" exact="ribavirin" post="used alone and in combination against infections in mice"/>
  <result pre="and B virusesAntivir Chem Chemother20061741859210.1177/09563202060170040317066897 190.SeoSet al.Combination therapy with amantadine," exact="oseltamivir" post="and ribavirin for influenza A infection: safety and pharmacokineticsAntivir"/>
  <result pre="virusesAntivir Chem Chemother20061741859210.1177/09563202060170040317066897 190.SeoSet al.Combination therapy with amantadine, oseltamivir and" exact="ribavirin" post="for influenza A infection: safety and pharmacokineticsAntivir Ther20131833778610.3851/IMP247523264438 191.FurutaYet"/>
  <result pre="sialidase therapy for respiratory viral infectionsAntiviral Res2013983401910.1016/j.antiviral.2013.04.01223602850 200.HaffizullaJet al.Effect of" exact="nitazoxanide" post="in adults and adolescents with acute uncomplicated influenza: a"/>
  <result pre="pneumonia: a future H5N1 treatment?Ann Intern Med2006145859960910.7326/0003-4819-145-8-200610170-0013916940336 202.ValetteMet al.Susceptibilities to" exact="rimantadine" post="of influenza A/H1N1 and A/H3N2 viruses isolated during the"/>
  <result pre="and 1989 to 1990Antimicrob Agents Chemother1993371022394010.1128/AAC.37.10.22398257151 203.ZieglerTet al.Low incidence of" exact="rimantadine" post="resistance in field isolates of influenza A virusesJ Infect"/>
  <result pre="influenza A virusesJ Infect Dis19991804935910.1086/31499410479115 204.DawsonJNeuraminidase inhibitor and amantadineLancet20003559222225410.1016/S0140-6736(05)72755-010881922 205.SuzukiHSaitoROshitaniHExcess" exact="amantadine" post="use and resistant virusesLancet20013589296191010.1016/S0140-6736(01)06919-711741673 206.ShihSRet al.Amantadine-resistant influenza A virus"/>
  <result pre="studyLancet1969276291026810.1016/S0140-6736(69)90639-44187541 209.BricaireFet al.Prevention of influenza A. Effectiveness and tolerance of" exact="rimantadine" post="hydrochloridePresse Med.199019269722137233 210.MontoASet al.Zanamivir prophylaxis: an effective strategy for"/>
  <result pre="A and B within householdsJ Infect Dis2002186111582810.1086/34572212447733 211.WelliverRet al.Effectiveness of" exact="oseltamivir" post="in preventing influenza in household contacts: a randomized controlled"/>
  <result pre="epidemic in the family environmentBull World Health Organ1969413677824908342 213.HaydenFGet al.Inhaled" exact="zanamivir" post="for the prevention of influenza in families. Zanamivir Family"/>
  <result pre="al.Management of influenza in households: a prospective, randomized comparison of" exact="oseltamivir" post="treatment with or without postexposure prophylaxisJ Infect Dis20041893440910.1086/38112814745701 215.McKimm-BreschkinJet"/>
  <result pre="sequence analysis and susceptibilities of influenza virus clinical isolates to" exact="zanamivir" post="and oseltamivirAntimicrob Agents Chemother200347722647210.1128/AAC.47.7.2264-2272.200312821478 216.HurtACet al.Susceptibility of human influenza"/>
  <result pre="from Australasia and South East Asia to the neuraminidase inhibitors" exact="zanamivir" post="and oseltamivirAntiviral Res2004621374510.1016/j.antiviral.2003.11.00815026200 217.BoivinGGoyetteNSusceptibility of recent Canadian influenza A"/>
  <result pre="the 2000–2002 influenza seasonsVirus Res20041031-2195710.1016/j.virusres.2004.02.03315163509 219.FerrarisOKesslerNLinaBSensitivity of influenza viruses to" exact="zanamivir" post="and oseltamivir: a study performed on viruses circulating in"/>
  <result pre="seasons. Wkly Epidemiol Rec, 2007. 82(17): p. 149-50. 223.WhitleyRJet al.Oral" exact="oseltamivir" post="treatment of influenza in childrenPediatr Infect Dis J20012021273310.1097/00006454-200102000-0000211224828 224.WardPet"/>
  <result pre="influenza pandemicJ Antimicrob Chemother200555Suppl 1i52110.1093/jac/dki01815709056 225.StephensonIet al.Neuraminidase inhibitor resistance after" exact="oseltamivir" post="treatment of acute influenza A and B in childrenClin"/>
 </snippets>
</snippetsTree>
